Argüelles-Martín F, González-Fernández F, Gentles M G, Navarro-Merino M
Department of Pediatrics, University Hospital Virgen de la Macarena, Seville, Spain.
Scand J Gastroenterol Suppl. 1989;156:43-7.
In order to evaluate the use of sucralfate in the treatment of children with reflux esophagitis, we studied 66 children aged from 4 months to 12 years (mean 5.9 years, SD 3.5) diagnosed to have gastroesophageal reflux by means of esophageal isotopic examination and radiology. An endoscopic examination was carried out in all cases. None of the patients suffered from kidney disease or had taken antacids, cimetidine, sucralfate or antirheumatic drugs in the two weeks prior to the study. Patients were divided into three groups matched according to age, grade of esophagitis, sex, nutritional state and semiology and treated with sucralfate in tablets, cimetidine, or sucralfate in suspension; no dietetic or postural measures were used. On days 14, 28, 42 and 56, clinical control was carried out and endoscopy was done on day 28, this being repeated on day 56 if the course was not satisfactory. From the statistical analysis of the results we deduce that there are no differences between the three groups. Therefore sucralfate appears to be a useful drug for the treatment of children with esophagitis due to GER.
为了评估硫糖铝在治疗小儿反流性食管炎中的应用,我们研究了66例年龄在4个月至12岁(平均5.9岁,标准差3.5)的儿童,这些儿童经食管同位素检查和放射学诊断为胃食管反流。所有病例均进行了内镜检查。在研究前两周,所有患者均未患有肾脏疾病,也未服用过抗酸剂、西咪替丁、硫糖铝或抗风湿药物。根据年龄、食管炎分级、性别、营养状况和症状学将患者分为三组并匹配,分别给予硫糖铝片、西咪替丁或硫糖铝混悬液治疗;未采取饮食或体位措施。在第14、28、42和56天进行临床对照,并在第28天进行内镜检查,如果疗程不满意,则在第56天重复进行。通过对结果的统计分析,我们推断三组之间没有差异。因此,硫糖铝似乎是治疗小儿GER所致食管炎的一种有效药物。